The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray.
Immunoscore
Irradiated rectal cancer
digital pathology
tissue microarray (TMA)
virtual microscopy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Feb 2020
29 Feb 2020
Historique:
received:
31
12
2019
revised:
02
02
2020
accepted:
17
02
2020
entrez:
4
3
2020
pubmed:
4
3
2020
medline:
4
3
2020
Statut:
epublish
Résumé
T cell density in colorectal cancer (CRC) has proven to be of high prognostic importance. Here, we evaluated the influence of a hyperfractionated preoperative short-term radiation protocol (25 Gy) on immune cell density in tumor samples of rectal cancer (RC) patients and on patient survival. In addition, we assessed spatial tumor heterogeneity by comparison of analogue T cell quantification on full tissue sections with digital T cell quantification on a virtually established tissue microarray (TMA). A total of 75 RC patients (60 irradiated, 15 treatment-naïve) were defined for retrospective analysis. RC samples were processed for immunohistochemistry (CD3, CD8, PD-1, PD-L1). Analogue (score 0-3) as well as digital quantification (TMA: 2 cores vs. 6 cores, mean T cell count) of marker expression in 2 areas (central tumor, CT; invasive margin, IM) was performed. Survival was estimated on the basis of analogue as well as digital marker densities calculated from 2 cores (Immunoscore: CD3/CD8 ratio) and 6 cores per tumor area. Irradiated RC samples showed a significant decrease in CD3 and CD8 positive T cells, independent of quantification mode. T cell densities of 6 virtual cores approximated to T cell densities of full tissue sections, independent of individual core density or location. Survival analysis based on full tissue section quantification demonstrated that CD3 and CD8 positive T cells as well as PD-1 positive tumor infiltrating leucocytes (TILs) in the CT and the IM had a significant impact on disease-free survival (DFS) as well as overall survival (OS). In addition, CD3 and CD8 positive T cells as well as PD-1 positive TILs in the IM proved as independent prognostic factors for DFS and OS; in the CT, PD-1 positive TILs predicted DFS and CD3 and CD8 positive T cells as well as PD-1 positive TILs predicted OS. Survival analysis based on virtual TMA showed no impact on DFS or OS. Spatial tumor heterogeneity might result in inadequate quantification of immune marker expression; however, if using a TMA, 6 cores per tumor area and patient sample represent comparable amounts of T cell densities to those quantified on full tissue sections. Consistently, the tissue area used for immune marker quantification represents a crucial factor for the evaluation of prognostic and predictive biomarker potential.
Sections du résumé
BACKGROUND
BACKGROUND
T cell density in colorectal cancer (CRC) has proven to be of high prognostic importance. Here, we evaluated the influence of a hyperfractionated preoperative short-term radiation protocol (25 Gy) on immune cell density in tumor samples of rectal cancer (RC) patients and on patient survival. In addition, we assessed spatial tumor heterogeneity by comparison of analogue T cell quantification on full tissue sections with digital T cell quantification on a virtually established tissue microarray (TMA).
METHODS
METHODS
A total of 75 RC patients (60 irradiated, 15 treatment-naïve) were defined for retrospective analysis. RC samples were processed for immunohistochemistry (CD3, CD8, PD-1, PD-L1). Analogue (score 0-3) as well as digital quantification (TMA: 2 cores vs. 6 cores, mean T cell count) of marker expression in 2 areas (central tumor, CT; invasive margin, IM) was performed. Survival was estimated on the basis of analogue as well as digital marker densities calculated from 2 cores (Immunoscore: CD3/CD8 ratio) and 6 cores per tumor area.
RESULTS
RESULTS
Irradiated RC samples showed a significant decrease in CD3 and CD8 positive T cells, independent of quantification mode. T cell densities of 6 virtual cores approximated to T cell densities of full tissue sections, independent of individual core density or location. Survival analysis based on full tissue section quantification demonstrated that CD3 and CD8 positive T cells as well as PD-1 positive tumor infiltrating leucocytes (TILs) in the CT and the IM had a significant impact on disease-free survival (DFS) as well as overall survival (OS). In addition, CD3 and CD8 positive T cells as well as PD-1 positive TILs in the IM proved as independent prognostic factors for DFS and OS; in the CT, PD-1 positive TILs predicted DFS and CD3 and CD8 positive T cells as well as PD-1 positive TILs predicted OS. Survival analysis based on virtual TMA showed no impact on DFS or OS.
CONCLUSION
CONCLUSIONS
Spatial tumor heterogeneity might result in inadequate quantification of immune marker expression; however, if using a TMA, 6 cores per tumor area and patient sample represent comparable amounts of T cell densities to those quantified on full tissue sections. Consistently, the tissue area used for immune marker quantification represents a crucial factor for the evaluation of prognostic and predictive biomarker potential.
Identifiants
pubmed: 32121328
pii: cancers12030563
doi: 10.3390/cancers12030563
pmc: PMC7139832
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Immunother Cancer. 2016 Sep 20;4:51
pubmed: 27660705
Cancer Lett. 2015 Nov 28;368(2):198-208
pubmed: 25592036
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34
pubmed: 15701862
Cancer Immunol Res. 2015 Oct;3(10):1123-1129
pubmed: 26081225
Cancer Lett. 2015 Nov 28;368(2):156-63
pubmed: 25911239
Cancer Manag Res. 2017 Jun 29;9:249-258
pubmed: 28721097
Clin Cancer Res. 2014 Apr 1;20(7):1891-9
pubmed: 24691640
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer Immunol Res. 2016 Nov;4(11):895-902
pubmed: 27803050
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Cancer Immunol Immunother. 2017 Jun;66(6):777-786
pubmed: 28289861
Proteomics. 2014 Mar;14(4-5):441-51
pubmed: 24339433
Int J Clin Oncol. 2016 Oct;21(5):946-952
pubmed: 26919982
Transl Res. 2015 Dec;166(6):721-732.e1
pubmed: 26209749
J Pathol. 2006 Apr;208(5):607-14
pubmed: 16435284
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21
pubmed: 24566864
JCI Insight. 2016 Jun 16;1(9):e87415
pubmed: 27699275
Oncoimmunology. 2013 Apr 1;2(4):e24116
pubmed: 23734335
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Semin Radiat Oncol. 2015 Jan;25(1):11-7
pubmed: 25481261
Hum Pathol. 2004 Nov;35(11):1347-52
pubmed: 15668891
Gut. 2017 Aug;66(8):1463-1473
pubmed: 27196573
Diagn Mol Pathol. 2004 Dec;13(4):213-6
pubmed: 15538111
J Immunol. 2018 Jan 1;200(1):347-354
pubmed: 29141863
Onco Targets Ther. 2019 May 14;12:3671-3682
pubmed: 31190869
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Am J Cancer Res. 2015 May 15;5(6):2064-74
pubmed: 26269765
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Br J Cancer. 2005 Apr 11;92(7):1209-14
pubmed: 15785745
Anal Quant Cytol Histol. 2010 Dec;32(6):333-40
pubmed: 21456345
Clin Cancer Res. 2015 Aug 15;21(16):3727-39
pubmed: 25869387
Genome Biol. 2015 Mar 31;16:64
pubmed: 25853550
Oncoimmunology. 2013 Oct 1;2(10):e26536
pubmed: 24404424
Eur Surg. 2016;48(6):352-356
pubmed: 28058043
Cancer Immunol Immunother. 2014 Jan;63(1):29-36
pubmed: 24052136
Eur J Cancer. 2016 Sep;65:52-60
pubmed: 27468145
Int J Cancer. 2006 May 1;118(9):2190-4
pubmed: 16331604
J Natl Cancer Inst. 1979 Nov;63(5):1229-35
pubmed: 291749
J Pathol Clin Res. 2017 Jan 13;3(1):58-70
pubmed: 28138402